Augustine Therapeutics NV, based in Leuven, Belgium, has raised €77.7 million in an oversubscribed Series A funding round co-led by Novo Holdings and Jeito Capital. The funds from this investment will further the clinical development of its lead candidate AGT-100216 for Charcot-Marie-Tooth disease, beginning Phase I trials shortly. Augustine is also exploring two additional programs for neurodegenerative and cardio-metabolic diseases, focused on novel HDAC6 inhibitors. The financing reflects confidence in Augustine’s innovative approach to therapeutics, particularly in addressing unmet needs in chronic diseases.
This significant financing is a testament to the innovative medicinal chemistry that Augustine was founded on, which acts via a unique mechanism of action.
The therapeutic potential of HDAC6 is widely recognized in our industry, but previous drug approaches have been sub-optimal, particularly for chronic diseases.
Collection
[
|
...
]